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Abstract
Background: There is a perception that kidney transplant recipients transferred from pediatric centers to adult care
have an increased risk of graft loss. It is not clear whether young adults transplanted in adult centers also suffer
from high graft loss rates.
Methods: We examined death censored graft survival in 3 cohorts of young patients transplanted at a single
center. Pediatric (PED) patients transplanted at the pediatric center were compared to a cohort of young adults
(YAD; age 18- < 25) and a cohort of adults (ADL; age 25-35).
Results: In a multivariate Cox model for death-censored graft survival, PED survival was statistically similar to the
YAD (HR 0.86, 95% CI 0.44, 1.7, p = 0.66), however the ADL cohort (HR 0.45, 95% CI 0.25, 0.82, p = 0.009)
demonstrated better survival. Admitted non-adherence rates were not different among cohorts. Patients were
transferred within a narrow age window (18.6 ± 1.0 age in years) but at a wide range of times from the date of
transplantation (5.1 ± 3.5 years) and with a wide range of graft function (serum creatinine 182 ± 81 μmol/L).
Conclusions: The perception that pediatric transfers do poorly reflects advanced graft dysfunction in some at the
time of transfer. The evidence also suggests that it is not the transfer of care that is the critical issue but rather
recipients, somewhere between the ages of 11-14 and 25, are a unique and vulnerable cohort. Effective strategies
to improve outcomes across this age group need to be identified and applied consistently.
Background
The transfer from pediatric to adult care is a challenging
area of medicine for adolescents with chronic diseases and
especially after kidney transplantation [1]. A high rate of
graft loss associated with suspected non-adherence after
transfer has been described in a small single center report
[2]. It has also been our perception that pediatric patients
transferring to our adult center have had a greater rate of
graft loss. We also had the impression that non-adherence
to medication was a key factor for inferior outcomes and
wondered whether differences in patient care after transfer
might trigger non-adherence. An alternative explanation
for this observation might be that some patients have fail-
ing grafts at transfer. However there are several more
recent papers that do not support an increased risk of
rejection or graft loss in pediatric kidney transplant recipi-
ents after their care has been transferred to an adult cen-
ter. Koshy et al showed stable graft loss rates before and
after transfer [3]. Van den Heuvel et al examined acute
rejection rates over time and found no increase after trans-
fer [4]. Both studies compared outcomes before and after
transfer using patients as their own controls. It is also not
clear from these reports whether adolescents transplanted
in adult centers suffer the same outcomes as pediatric
transplant recipients who transfer to adult care and
whether these outcomes are inferior to older recipients.
The purpose of this report was to compare graft survival
in young adults transplanted in the pediatric hospital to
older adults transplanted in the adult hospital. The null
hypothesis was there would be no difference in graft survi-
val. However we anticipated that survival in the pediatric
c o h o r tw o u l db ei n f e r i o r .I ft h i sw a st r u ew ew o u l db e
compelled to change our transfer process.
Methods
This is a single center program retrospective chart review
of consecutive solitary kidney recipients transplanted
between January 1990 and December 2009. All recipients
who were age ≤35 at the time of transplantation and
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included in the analysis. Permission for the study was
obtained from our institution ethics review board. Data
was abstracted from the program’s database and indivi-
dual patient charts and flow sheets.
Pediatric kidney transplants were performed at the IWK
Health Center and adults at the QEII Health Sciences
Center (geographically separate sites). However the sur-
gery is performed by the same surgeons. Medical care is
provided by pediatric and adult nephrologists at the
respective sites. Care is transferred from pediatric to adult
medicine at approximately age 18 years. A transfer letter is
sent by the pediatric nephrologist to the adult transplant
nephrologist along with all relevant records. The pediatric
clinic nurse contacts the adult nurse to review the impor-
tant issues and set the date of transfer. A visit is scheduled
within 3 months in the adult clinic.
To test the above hypothesis three cohorts were deter-
mined based on age at transplantation and place of trans-
plant. All pediatric (PED) were transplanted in the
pediatric hospital. This cohort was compared to 2 older
cohorts, who were transplanted in the adult hospital, con-
sisting of young adults (age 18 to < 25, YAD) and older
adults (age 25 to 35, ADL),
The status of the patients at transfer was defined at first
visit to the adult center. The study examined age at trans-
fer, graft function (serum creatinine), blood pressure, phos-
phate control, and immunosuppressive therapy. The
number of laboratory tests performed was also examined
in the year pre and post transfer. We examined the causes
of graft loss and defined non-adherence as a contributor to
graft loss only if the patient admitted discontinuation of an
immunosuppressive medication to an attending physician.
Descriptive statistics are presented as mean and stan-
dard deviation or percentages. Differences between groups
for variables of interest were performed using parametric
and non-parametric tests, where appropriate. To exclude
potential differences in technical (more challenging vascu-
lar anastomosis) and survival bias (patients with early graft
loss less likely to transfer with a functioning transplant)
death censored graft survival was examined in patients
with functioning kidney transplant at 1 year. Pediatric
(PED) graft survival was compared to YAD and ADL
using Kaplan-Meier survival tested by log-rank starting at
year 1 as time zero. Other covariates were examined for
associations with graft survival and these included gender,
acute rejection within the first year, donor age, organ
source, delayed graft function (need for dialysis), diabetes
mellitus at time of transplant, HLA mismatch, peak PRA
(%), immunosuppression at transplantation (type of calci-
neurin inhibitor and type of adjunctive therapy), and reci-
pient and donor CMV status. Cold ischemia time could
not be examined given the large amount of missing data.
Pre transplant PRA was only examined in deceased
donation as this test was not performed on live donor reci-
pients. The Kaplan-Meier method was used to test for sig-
nificant univariate associations with graft survival. Donor
age and peak PRA were also tested by examining tertiles
for donor age and 0% versus > 0% for PRA (deceased
organ source only). Covariates with a level of significance
of < 0.10 were included into the final multivariate Cox
model. Significance was tested at the 5% level. Statistical
analyses were performed using SPSS 15.0 software (Chi-
cago, IL).
Results
There were 247 transplants performed in 224 recipients
between January 1990 and December 2009. Only 7
(3.1%) were not Caucasian. Table 1 shows the baseline
demographics for the three age cohorts. Other than age,
diabetes mellitus status and initial immunosuppression,
the 3 patient groups were similar at baseline.
Twenty six transplants were lost within 1 year (PED- 7
(12.5%); YAD-6 (11.1%); ADL-13 (9.5%)) and these graft
outcomes were excluded. All 7 of the pediatric graft
losses occurred at the pediatric center. The remaining
were distributed to the PED (n = 49), YAD (n = 48) and
ADL (n = 124) cohorts. Figure 1 shows the Kaplan-Meier
death censored graft survival for the 3 age cohorts. The
survival for the first 2 cohorts (PED and YAD) are almost
superimposed where as the graft survival is statistically
better (p = 0.04) in the oldest age cohort (ADL; age 25-
35). There were 17 patients that died with a functioning
graft (PED-2; YAD-2; ADL-13)
In a multivariate Cox model for death censored graft sur-
vival, pre-emptive transplantation (HR 0.18, 95% CI 0.07,
0.45, p < 0.001), CMV D+R- status (HR 0.30, 95% CI 0.13,
0.72, p = 0.006) and male gender (HR 0.55, 95% CI 0.36,
0.90, p = 0.017) were associated with much better out-
comes whereas acute rejection was associated with an
inferior outcome (HR 2.3, 95% CI 1.4, 3.8, p = 0.001). In
comparison to the PED group the YAD was statistically
similar (HR 0.86, 95% CI 0.44, 1.7, p = 0.66). However the
older age category demonstrated better survival (HR 0.45,
95% CI 0.25, 0.82, p = 0.009). HLA mismatch, diabetes
mellitus, PRA, immunosuppressive therapy, organ source,
and donor age were not significant.
Of the 49 PED cohort 24 transferred to the adult
program with a functioning transplant. Of these 24, 18
were followed at this center and the remaining 6 were
followed elsewhere. Table 2 shows the characteristics of
the patients on transfer to this institution. Of these, 6
had a serum creatinine > 180 μmol/L at transfer and all
of these eventually failed. Three of these had advanced
dysfunction (serum creatinine > 300 μmol/L) and all
failed within 2 years.
In the PED group, 4 (21%) of the 19 graft failures
were admitted non-adherers whereas the number in the
Kiberd et al. BMC Nephrology 2011, 12:54
http://www.biomedcentral.com/1471-2369/12/54
Page 2 of 6YAD cohort was 3 (19%) of 18 graft losses and in the
ADL group was 6 (20%) of 30 graft losses.
Discussion
The major finding is that there does not appear to be any
difference in graft survival for young recipients trans-
planted at the pediatric center and those young adults
transplanted at the adult center. Both groups appear to
do worse than a slightly older cohort. This study does
not provide any evidence that the transfer from pediatric
to adult care is responsible for any increase in graft fail-
ure. The perception of early graft loss after transfer likely
reflects advanced graft dysfunction in some patients. The
more important implication of this report is our concep-
tion of the issue which might identify appropriate areas
of study. Conceptually, it is not the transfer of care that
is the critical issue but rather recipients, somewhere
b e t w e e nt h ea g e so f1 1 - 1 4a n d2 5 ,a r eau n i q u ea n d
vulnerable cohort. Effective strategies across this age
group need to be identified and applied consistently.
The findings of this study appear to be at odds with a
Government of Accountability Office (GAO-07-1117)
report of US kidney transplant recipients. In an analysis of
the USRDS database of kidney transplant recipients trans-
planted between 1997 and 2000, researchers also created 3
cohorts of patients (pediatric-1, 218, transition-2, 148 and
adult-49, 940) and examined survival [5]. At 5 years post
transplantation there were more graft losses in transitional
patients (33%) than pediatric (16%) and adult (28%)
patients. However, the Scientific Registry of Transplanta-
tion Recipients (SRTR) report showed that pediatric recipi-
ents between the age of 11-17 have the lower 1, 3, and 5
year graft survival compared to recipients age < 11 and age
18-34 [6]. The GAO study did not perform appropriate
survival analyses, and neither the GAO nor the SRTR
report tested for statistical significance in an adjusted
Table 1 Baseline Characteristics of the Three Age Cohorts at Time of Transplantation
Pediatric
PED
N=5 6
Young Adult
YAD
N=5 4
Adult
ADL
N = 137
p-value
Age years 11 ± 5 21 ± 2 30 ± 3 < 0.001
Gender male 29 (52%) 31 (57%) 79 (58%) 0.75
Deceased Donor 31 (55%) 23 (43%) 74 (54%) 0.34
Donor Age years 36 ± 12 37 ± 14 36 ± 15 0.99
Pre-emptive 18 (32%) 15 (28%) 33 (24%) 0.51
1
st graft 42 (80%) 45 (83%) 103 (75%) 0.44
CMV D+/R- 12 (21%) 11 (20%) 29 (21%) 0.98
HLA Mismatch 3.5 ± 1.1 3.7 ± 1.4 3.8 ± 1.4 0.35
Delayed Graft Function 8 (14%) 5 (9%) 18 (13%) 0.69
Peak PRA % 4 ± 15 5 ± 15 4 ± 10 0.88
Diabetes Mellitus 0 4 (8%) 20 (18%) 0.007
Rejection within Year 1 22 (39%) 16 (30%) 41 (30%) 0.41
Year of Transplant
1990-1994 13 (23%) 22 (41%) 45 (33%) 0.055
1995-1999 18 (32%) 9 (17%) 42 (31%)
2000-2004 14 (25%) 11 (20%) 30 (21%)
2005-2009 11 (20%) 12 (22%) 20 (14%)
Immunosuppression
Individual 25 (45%) 5 (9.3%) 34 (25%) < 0.001
Depleting Antibody 50 (89%) 38 (70%) 94 (69%) < 0.001
Cyclosporine (CSA) 4 (7%) 16 (30%) 43 (31%) < 0.001
Tacrolimus (TAC) 40 (71%) 22 (41%) 50 (36%) < 0.001
Azathioprine (AZA) 13 (23%) 29 (54%) 75 (55%) < 0.001
Mycophenolate (MPA)
Immunosuppression
Combinations 45 (80%) 21 (39%) 49 (36%) < 0.001
CSA/AZA 10 (18%) 17 (31%) 35 (26%)
CSA/MPA 0 1 (1.8%) 1 (0.7%)
TAC/AZA 4 (7%) 12 (22%) 41 (30%)
TAC/MMF 1 (1.8%) 3 (5.5%) 11 (8%)
Other
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18-25) and older adults (age 25-35). We suspect that with
further analysis of this registry, subjects transplanted within
the 18-25 year age will be seen to have death censored
graft survival rates that are similar to 11-17 year olds and
both will be inferior to graft survival in 25 to 35 year olds.
The Canadian study by Koshy et al found relatively con-
stant graft loss rates of about 5-6 per 100 patient years of
exposure in age intervals of 14-17.9, 18-19.9 and 20-23.9
[2]. Although some of the recipients transplanted at age
11-17 would have lost their grafts after transfer, the results
w o u l da l s ob ec o n s i s t e n tw i t ht h ec o n c e p tt h a ty o u n g
adults somewhere between ages of 11 and 14 to 25 (the
lower threshold is unclear) are a vulnerable cohort rather
than the transfer of care being the critical issue.
The literature on transfer to adult care in kidney trans-
plantation is limited. There is a concern that adolescents
feel disenfranchised and alienated in the process [7]. Some
have advocated a planned transfer that might include the
adult nephrologist and nurse visiting the patient in the
pediatric center prior to transfer, a joint transition clinic
and programmed visits to the adult center prior to transfer
[7]. However others have not been able to demonstrate the
benefit of a targeted transition clinic [8]. The studies are
small but all highlight the challenges of transfer. These
and others are concerned about non-adherence [7-9]. It is
possible that adolescents and young adults are at a vulner-
able time regardless of the initial site of care and whether
there is a transfer between centers. Greenstein and Siegal
and others have characterized a subgroup of non-adherers
as ‘invulnerable’. These tend to be younger, less well
educated, hide their non-adherence and do not believe
missing medication will hurt them [9,10]. Centers caring
for adolescent and young adults may need to confront this
specific belief.
The study did not find a greater rate of admitted non-
adherence as a cause of graft failure despite our initial per-
ception that this might explain observed differences. It is
difficult to know the extent of the non-adherence in the
entire group since often the admission is only detected at
graft failure. No measures of non-adherence have high
sensitivities or specificities [11]. We utilized admitted non-
adherence with immunosuppressant medications as a spe-
cific variable in this analysis, but did not ask all patients in
a standardized fashion [12]. We did not evaluate rates of
covert non-adherence in this study (for example low or
variable drug levels, unfilled prescriptions, etc). It is inter-
esting to note that females had inferior outcomes in com-
parison to their counterparts. There is some suggestion
that body image may play a role in non-adherence in
pediatric transplant recipients however there was no clear
indication of greater non-adherence in females in this
study and gender has not consistently been associated
with non-adherence in pediatric transplant recipients
[13,14]. Whether some of the difference in graft survival
exists between the ADL group and the younger 2 cohorts
from undetected non-adherence remains speculative.
Part of the perception that patients do worse after trans-
fer is that some are transferred with failing allografts lead-
ing to dialysis within a short time period. Of the cohort
transferred almost half have lost their transplant. Age was
the reason for transfer, not graft function. Patients were
transferred within a narrow age window but at a wide
range of times from the date of transplantation and with a
wide range of graft function. Many of the patients trans-
ferred have significant ‘mileage’ on their grafts and this is
the more likely explanation for the perception of inferior
outcomes. Overall the care of the patients at transfer was
excellent with well controlled blood pressure and serum
phosphate. It is interesting to note that the number of
laboratory tests in the year after transfer was about half of
the number in the year before transfer. Although there
were significant differences in the types of initial immuno-
suppression between cohorts this did not explain the dif-
ferences detected. Whether the differences in outcomes
could be related to greater immune activity or greater
non-immunologic (growth and hormonal changes) stress
in younger recipients remain a distinct possibility and
should not be discounted.
The study has limitations. To test the hypothesis ade-
quately that transfer of care is the critical event there
would need to be a control trial randomizing pediatric kid-
ney recipients at age 18 to continued follow up at the
pediatric center compared to transfer and follow up to an
adult center. As analyzed in this study a significant
Numbers at Risk 
PED     49                32                 12                  2              
YAD     48                29                 14                  5
ADL    125               86                  48                13
Figure 1 Death Censored Graft Survival (Kaplan-Meier) after
year 1 and stratified by Age Group (PED, Pediatric; YAD,
Young Adult age < 25; ADL, Adult age 25-35).
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have been missed. A sample size of nearly 700 patients
would be required to detect a hazard ratio of 0.80 with a
power of 80%. This is a single center Canadian study in a
predominately white population with universal health care.
Other centers might experience different outcomes. A pro-
spective comprehensive standardized non-adherence study
would better detect this as a cause of differences in survival
between cohorts than this retrospective analysis. We sus-
pect that non-adherence remains a major explanation but
cannot prove it.
Immunosuppression was significantly different between
groups at baseline but was not a significant predictor of
outcomes. This may have been the small sample size or
the fact that many pediatric patients had medication
changes, as demonstrated in the composition of drug
t h e r a p i e sa tt r a n s f e r( T a b l e2 ) .T h em o r el i k e l ye x p l a n a -
tion is that the newer therapies have reduced acute rejec-
tion rates and improved 1 year graft survival but have not
greatly improved survival after the first year [15]. In a
recent study by Opelz, no significant survival differences
could be detected between recipients treated initially
with cyclosporine versus tacrolimus or mychophenolate
versus azathioprine [16]. The finding that CMV D+R-
recipients fared better was a surprise finding of the study
and is largely unexplained. Most studies show that these
recipients are at increased risk of both death and graft
loss [17]. All patients would have received prophylaxis at
both centers. The protocols have evolved over time with
IVIG and acyclovir in the early years to the current strat-
egy of oral valganciclovir.
Conclusions
What this study identifies is that both pediatric patients
p r i o rt ot r a n s f e ra n da d o l e s c e n t st r a n s p l a n t e di nt h e
adult center are vulnerable and likely need similar inter-
ventions. These might include relatively more immuno-
suppression, better non-immunosuppressive renal
protection strategies, effective education with regards to
adherence, and better coping strategies. A large rando-
mized controlled intervention trial would be needed to
establish benefit. At present there are likely multiple
strategies that might be beneficial and the preferred
strategy would need to be established. The study does
not negate the fact that adolescents transferring to adult
medicine require special attention and expertise, but
rather the date of transfer is an artificial time point and
focusing at this point may miss opportunities to
improve outcomes. Further research in this vulnerable
cohort deserves our greater attention.
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